Miller Anestesia

130. Biggins SW, Kim WR, Terrault NA, et al: Evidence-

based incorporation of serum sodium concentration

into MELD. Gastroenterology 130:1652-1660, 2006.

131. Salerno F, Merli M, Cazzaniga M, et al: MELD score

is better than Child-Pugh score in predicting

3-month survival of patients undergoing transjugu-

lar intrahepatic portosystemic shunt. J Hepatol

36:494-500, 2002.

132. Friedman LS: The risk of surgery in patients with

liver disease. Hepatology 29:1617-1623, 1999.

133. Sleeman D, Namias N, Levi D, et al: Laparoscopic

cholecystectomy in cirrhotic patients. J Am Coll

Surg 187:400-403, 1998.

134. Aranha GV, Kruss D, Greenlee HB: Therapeutic

options for biliary tract disease in advanced cirrho-

sis. Am J Surg 155:374-377, 1988.

135. Azoulay D, Buabse F, Damiano I, et al: Neoadjuvant

transjugular intrahepatic portosystemic shunt: A

solution for extrahepatic abdominal operation in

cirrhotic patients with severe portal hypertension. J

Am Coll Surg 193:46-51, 2001.

136. Friedman LS, Maddrey WC: Surgery in the patient

with liver disease. Med Clin North Am 71:453-476,

1987.

137. Seltzer JL, Goldberg ME, Larijani GE, et al: Prosta-

cyclin mediation of vasodilation following mesen-

teric traction. Anesthesiology 68:514-518, 1988.

138. Meierhenrich R, Gauss A, Vandenesch P, et al: The

effects of intraabdominally insufflated carbon

dioxide on hepatic blood flow during laparoscopic

surgery assessed by transesophageal echocardiogra-

phy. Anesth Analg 100:340-347, 2005.

139. MacIntosh EL, Minuk GY: Hepatic resection in

patients with cirrhosis and hepatocellular carci-

noma. Surg Gynecol Obstet 174:245-254, 1992.

140. Wu CC, Ho WL, Yeh DC, et al. Hepatic resection of

hepatocellular carcinoma in cirrhotic livers: Is it

unjustified in impaired liver function? Surgery

120:34-39, 1996.

141. Lau H, Man K, Fan ST, et al: Evaluation of preope-

rative hepatic function in patients with hepatocellu-

lar carcinoma undergoing hepatectomy. Br J Surg

84:1255-1259, 1997.

142. Bruix J, Castells A, Bosch J, et al: Surgical resection

of hepatocellular carcinoma in cirrhotic patients:

Prognostic value of preoperative portal pressure.

Gastroenterology 111:1018-1022, 1996.

143. Klemperer JD, Ko W, Krieger KH, et al: Cardiac

operations in patients with cirrhosis. Ann Thorac

Surg 65:85-87, 1998.

144. Bizouran P, Ausseur A, Desseigne P, et al: Early and

late outcome after elective cardiac surgery in

patients with cirrhosis. Ann Thorac Surg 67:1334-

1338, 1999.

145. Filsoufi F, Slazberg SP, Rahmanian PB, et al: Early

and late outcomes of cardiac surgery in patients

with liver cirrhosis. Liver Transpl 13:990-995, 2007.

146. Koizumi M, Matsumoto N, Uede K: Influences of

cardiopulmonary bypass and fentanyl anesthesia on

hepatic circulation and oxygen metabolism in

beagles. Anesth Analg 96:1177-1187, 1998.

147. Okano N, Miyoshi S, Owada R, et al: Impairment of

hepatosplanchnic oxygenation and increase of

serum hyaluronate during normothermic and mild

hypothermic cardiopulmonary bypass. Anesth

Analg 95:278-286, 2002.

148. Nyberg LM, Pockros PJ: Postoperative jaundice. In

Schiff ER, Sorrell MF, Maddrey WC (eds): Schiff’s

Diseases of the Liver, 8th ed. Philadelphia, Lippin-

cott-Raven, 1999, pp 599-605.

149. Thomas AT: Autoimmune hemolytic anemias. In

Lee GR, Foerster J, Lukens J, et al (eds): Wintrobe’s

Clinical Hematology, 10th ed. Baltimore, Williams

& Wilkins, 1999, pp 1233-1263.

150. Garcia MJ, Vander Oort P, Stewart W, et al: Mecha-

nisms of hemolysis with mitral prosthetic regurgi-

tation:

Study

using

transesophageal

echocardiography and fluid dynamic simulation. J

Am Coll Cardiol 27:399-406, 1996.

151. Zuck TF, Basinger TA, Peck CC, et al: The in vivo

survival of red blood cells stored in modified CDP

with adenine: Report of a multi-institutional coo-

perative effort. Transfusion 17:374-382, 1972.

152. Black M: Acetaminophen hepatotoxicity. Gastroen-

terology 78:382-392, 1980.

153. Zimmerman HJ, Lewis JH: Chemical and toxin-

induced hepatotoxicity. Gastroenterol Clin North

Am 24:1027-1045, 1995.

154. Vanderstigel M, Zafrani ES, Lejonc JL, et al: Allopu-

rinol hypersensitivity syndrome as a cause of

hepatic fibrin-ring granulomas. Gastroenterology

90:188-190, 1986.

155. Lewis JH, Ranard RC, Caruso A, et al: Amiodarone

hepatotoxicity: Prevalence, clinicopathologic corre-

lations among 104 patients. Hepatology 9:679-685,

1989.

156. Chiturri S, Farrell GC: Drug-induced cholestasis.

Semin Gastrointest Dis:12113-12124, 2001.

157. McGoldrick MD, Bailie GR: Non-narcotic analge-

sics: Prevalence and estimated economic impact of

toxicities. Ann Pharmacother 21:221-227, 1997.

158. Schein PS, Winokar SH: Immunosuppressive and

cytotoxic chemotherapy: Long term complications.

Ann Intern Med 82:84-95, 1975.

159. Tracleer package insert.

160. Speeg KV, Bay MK: Prevention and treatment of

drug-induced liver disease. Gastroenterol Clin

North Am 24:1047-1064, 1995.

161. Ben-Yehuda A, Bloom A, Lijovitzky G: Chlorpro-

mazine-induced liver and bone marrow granulo-

mas associated with agranulocytosis. Isr J Med Sci

26:449-451, 1990.

162. Cersosimo RJ: Hepatotoxicity associated with cis-

platin chemotherapy. Ann Pharmacother 27:438-

441, 1993.

163. Pearson K, Zimmerman HJ: Danazol and liver

damage. Lancet 1:645-646, 1980.

164. Lee WM: Drug-induced hepatotoxicity. N Engl J

Med 333:1118-1127, 1995.

165. Kirby B, Keaveney A, Brophy D: Abnormal liver

function tests induced by dapsone in a patient with

dermatitis and herpetiformis and primary sclero-

sing cholangitis. Br J Dermatol 141:172-173, 1999.

166. Forns X, Caballeria J, Bruguera M, et al: Disulfiram-

induced hepatitis: Report of four cases and review

of the literature. J Hepatol 21:853-857, 1994.

167. King PD, Blitzer BL: Drug induced cholestasis:

Pathogenesis and clinical features. Semin Liver Dis

10:316-321, 1990.

168. Bosse GM, Matyunas NJ: Delayed toxidromes. J

Emerg Med 17:679-690, 1999.

169. Ludwig J, Kim CH, Wiesner RH, Krom RA: Floxu-

ridine-induced sclerosing cholangitis: An ischemic

cholangiopathy? Hepatology 9:215-218, 1989.

170. Scharer L, Smith JD: Serum transaminase elevations

and other hepatic abnormalities in patients receiving

isoniazid. Ann Intern Med 71:1113-1116, 1969.

171. Vitug AC, Goldman JM: Hepatotoxicity from anti-

thyroid drugs. Horm Res 21:229-234, 1985.

172. Leonard PA, Clegg DO, Carson CC, et al: Low dose

pulse methotrexate in rheumatoid arthritis: An 8

year experience with hepatotoxicity. Clin Rheuma-

tol 6:575-582, 1987.

173. Neuberger J, Kenna JG, Nouri AK, Williams R:

Antibody-mediated hepatocyte injury in methyl-

dopa-induced hepatotoxicity. Gut 26:1233-1239,

1985.

174. Patterson DJ, Dew EW, Gyorkey F, et al: Niacin

hepatitis. South Med J 76:240-241, 1983.

175. Manoukian AV, Carson JL: Nonsteroidal anti-infla-

mmatory drug-induced hepatic disorders: Inci-

dence and prevalence. Drug Safe 15:64-71, 1996.

176. Zimmerman HJ, Lewis JH: Drug-induced cholesta-

sis. Med Toxicol 2:112-160, 1987.

177. Zimmerman HJ: Hepatotoxicity. Dis Mon 39:675-

787, 1993.

178. Adcock KG, MacElroy DE, Wolford ET, et al: Pemo-

line therapy resulting in liver transplantation. Ann

Pharmacother 32:422-425, 1998.

179. MMWR Morb Mortal Wkly Rep 50733, 2001.

180. Wokke J: Riluzole. Lancet 348:795-799, 1996.

181. Haupt NA, Rovere GD: Anabolic steroids: A review

of the literature. Am J Sports Med 12:469-475, 1984.

182. Lindgren A, Olsson R: Liver damage associated with

low dose oral contraceptives. J Intern Med 234:287-

292, 1993.

183. Monteith DK, Emmerling MR, Garvin J, Theiss JC:

Cytotoxicity study of tacrine, structurally and phar-

macologically related compounds using rat hepato-

cytes. Drug Chem Toxicol 19:71-75, 1996.

184. Hunt CM, Washington K: Tetracycline-induced bile

duct paucity and prolonged cholestasis. Gastroente-

rology 107:1844-1847, 1994.

185. Olanow CW: Tolcapone and hepatotoxic effects.

Tasmar Advisory Panel. Arch Neurol 57:263-267,

2000.

186. Chung C, Buchman AL: Postoperative jaundice and

total parental nutrition-associated hepatic dys-

function. Clin Liver Dis 6:1067-1084, 2002.

187. Rimmer EM, Richens A: An update on sodium val-

proate. Pharmacotherapy 5:171-185, 1985.

188. Geubal AA, DeGalocsy C, Rahirer J, Dive C: Liver

damage caused by therapeutic vitamin A adminis-

tration: Estimation of dose-related toxicity in 41

cases. Gastroenterology 100:1701-1709, 1991.

189. Reinus JF, Persky S, Burkiewicz JS, et al: Severe liver

injury after treatment with the leukotriene antago-

nist zafirlukast. Ann Intern Med 133:964-968,

2000.

190. Whiting PW, Clouston A, Kerlin P: Black cohosh

and other herbal remedies associated with acute

hepatitis. Med J Aust 177:440-443, 2002.

191. Benninger J, Schneider HT, Schuppan D, et al: Acute

hepatitis induced by greater celandine (Chelido-

nium majus). Gastroenterology 117:1234-1237,

1999.

192. Gordon DW, Rosenthal G, Hart J, et al: Chaparral

ingestion: The broadening spectrum of liver injuries

caused by herbal medications. JAMA 273:489-490,

1995.

193. Winship KA: Toxicity of comfrey. Adverse Drug

React Toxicol Rev 10:47-59, 1991.

194. Miller LG: Herbal medicinals: Selected clinical con-

siderations focusing on known or potential drug-

herb interactions. Arch Intern Med 158:2200-2211,

1998.

195. Lekhelal M, Pessayre D, Lereau JM, et al: Hepato-

toxicity of the herbal medicine germander: Meta-

bolic activation of its furano diterpenoids by

cytochrome P450 3A depletes cytoskeleton-asso-

ciated protein thiols and forms plasma membrane

blebs in hepatocytes. Hepatology 24:212-221,

1996.

196. Horowitz RS, Feldhaus K, Dart RC, et al: The clinical

spectrum of Jin Bu Huan toxicity. Arch Intern Med

156:899-903, 1996.

197. Wooltorton E: Herbal kava: Reports of liver toxicity.

CMAJ 166:777-780, 2002.

198. Stedman C: Herbal hepatotoxicity. Semin Liver Dis

22:195-206, 2002.

199. Haouzi D, Lekehal M, Moreau M, et al: Cytochrome

P450-generated reactive metabolites cause mito-

chondrial permeability transition, caspase activa-

tion, and apoptosis in rat hepatocytes. Hepatology

32:303-311, 2000.

200. Moseley RH: Sepsis-associated cholestasis. Gas-

troenterology 112:302-306, 1997.

201. Grieg JD, Krukowski ZH, Matheson NA: Surgical

morbidity and mortality in one hundred twenty

nine patients with obstructive jaundice. Br J Surg

75:216-219, 1988.

202. Gonullu NN, Canturk NZ, Utkan NZ, et al: Factors

affecting surgical morbidity and mortality in

patients with obstructive jaundice. Materia Medica

Polona 30:6-11, 1998.

203. Dixon JM, Armstrong CP, Duff SW, Davies GC:

Factors affecting morbidity and mortality after

surgery for obstructive jaundice: A review of 373

patients. Gut 24:845-852, 1983.

204. Wait RB, Kahng KU: Renal failure complicating

obstructive jaundice. Am J Surg 157:256-263, 1989.

205. Green J, Better OS: Systemic hypotension and renal

failure in obstructive jaundice—mechanistic and

therapeutic aspects. J Am Soc Nephrol 5:1853-1871,

1995.

206. Kramer HJ, Schwarting K, Backer A, Meyer-Lehnert

H: Renal endothelin system in obstructive jaundice:

Its role in impaired renal function of bile-duct

ligated rats. Clin Sci 92:579-585, 1997.

1918

Anestesia por subespecialidades en el adulto